Weekly Recap: Intismeran Phase III success and FDA approval of mFLU

Moderna, Inc. (NASDAQ:MRNA) is pivoting from COVID to a broad mRNA platform—winning FDA approval for mFLU, reporting strong Phase III Intismeran results that accelerate vaccine, oncology and rare—disease programs, and scheduling investor and scientific presentations as CEO Stéphane Bancel touts fas…